Qiagen, Merck Team on HPV Screening, Vaccination in Rwanda | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen will provide molecular diagnostics screening to women in Rwanda as part of a national cervical cancer prevention effort announced today.

As part of the initiative announced by Merck, Qiagen, and the government of Rwanda, Qiagen will provide screening for women between the ages of 35 and 45, and Merck will vaccinate girls between 12 and 15 years of age during the first three years of the program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.